生活習慣病のマルチケア

出版社： 日本医学出版ヘルスケア・アカデミー
著者：
発行日： 2000-09-25
分野： 臨床医学：内科  >  内科学一般
ISBN： 9784931419421
電子書籍版： 2000-09-25 （初版第1刷）
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,950 円(税込)

購入する

商品紹介

「高血圧」「糖尿病」「高脂血症」の既刊の特集をまとめ、更に生活習慣病の実際の対策についての座談会を巻頭に入れて「生活習慣病のマルチケア」とした。

目次

  • 表紙
  • 序文
  • 執筆者
  • 目次
  • 巻頭座談会 生活習慣病のマルチケア
  • I. 降圧薬
  • 〔降圧薬 - 選択と適正使用のための基礎知識〕
  • 1. 薬物療法開始のタイミング
  • 2. 降圧薬の分類とその特徴
  • 3. 降圧薬の選択と適応
  • 4. カルシウム拮抗薬 - その特徴と適正使用
  • 5. アンジオテンシン変換酵素阻害薬 - その特徴と適正使用
  • 6. アンジオテンシン受容体タイプ1拮抗薬 - その特徴と適正使用
  • 7. 交感神経遮断薬 - その特徴と適正使用
  • 8. 利尿薬 - その特徴と適正使用
  • 9. コンプライアンスとQuality of Life
  • 10. 軽症高血圧患者に対する適正使用
  • 11. 高齢者に対する適正使用
  • 12. 妊婦に対する適正使用
  • 13. 小児に対する適正使用
  • 14. 降圧薬の副作用と対策
  • 15. 降圧薬の薬物相互作用
  • 〔各種疾患と高血圧合併時の降圧薬の選択と適正使用〕
  • 16. 腎障害患者に対する適正使用
  • 17. 脳血管障害患者に対する適正使用
  • 18. 心疾患患者に対する適正使用
  • 19. 肥満者・糖尿病患者に対する適正使用
  • 20. 高脂血症患者に対する適正使用
  • 降圧薬 - 私の処方 ( 1 )
  • 降圧薬 - 私の処方 ( 2 )
  • II. 糖尿病治療薬
  • 〔糖尿病治療薬 - 選択と適正使用のための基礎知識〕
  • 1. α - グルコシダーゼ阻害薬
  • 2. メトホルミン
  • 3. スルフォニル尿素薬 ( SU薬 )
  • 4. 非SUインスリン分泌刺激薬
  • 5. インスリン抵抗性改善薬
  • 6. インスリン製剤
  • 〔各種病態における糖尿病治療薬の選択〕
  • 7. 肥満2型糖尿病
  • 8. 高脂血症を合併する2型糖尿病
  • 9. 高血圧を合併した2型糖尿病の治療
  • 10. 動脈硬化症合併2型糖尿病
  • 〔各種糖尿病治療薬の選択に注意を要する病態〕
  • 11. 高齢者糖尿病
  • 12. 小児期発症2型糖尿病
  • 13. 妊娠糖尿病
  • 14. 末梢神経障害高度例
  • 糖尿病治療薬 - 私の処方 2型糖尿病に対する第一選択薬は
  • III. 高脂血症治療薬
  • 〔高脂血症治療薬 - 選択と適正使用のための基礎知識〕
  • 1. はじめに - 序にかえて
  • 2. 高脂血症治療のガイドライン
  • 3. 高脂血症治療 - 一般療法
  • 4. 高脂血症治療 - 薬物療法
  • 5. 高齢者に対する適正使用
  • 6. 小児に対する適正使用
  • 7. 婦人高脂血症 ( 閉経前, 閉経後 ) に対する適正使用
  • 8. 高脂血症治療薬の副作用・相互作用対策
  • 〔各種疾患と高脂血症治療薬の選択と適正使用〕
  • 9. 高血圧を合併した高脂血症
  • 10. 糖尿病を合併した高脂血症
  • 11. 虚血性心疾患を合併した高脂血症
  • 12. シンドロームX
  • 13. 肥満症
  • 〔疫学・大規模臨床試験〕
  • 14. 疫学・大規模臨床試験 - いかに実地診療に生かすか
  • 高脂血症治療薬 - 私の処方 ( 1 )
  • 高脂血症治療薬 - 私の処方 ( 2 )
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 降圧薬

P.18 掲載の参考文献
1) IPPPSH Collaborative Group : Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxiprenolol-The Intemational Prospective Primary Prevention Study in Hypertension (IPPPSH) -. J Hypertens 3 : 379, 1985
 
2) Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure : The sixth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 157 : 2413, 1997
 
3) Management of Committee of the Australian Therapeutic Trial in Mild Hypertension : Untreated mild hypertension. Lancet 1 : 185, 1982
PubMed
4) Wilson P W F : Established risk factors and coronary artery disease -the Framingham study-. Am J Hypertens 7 : 7S, 1994
 
5) Jackson R, Barham P, Bills J et al : Management of raised blood pressure in New Zealand-a discussion document-. Br Med J 307 : 107, 1993
 
6) Intersalt Cooperative Research Group : Intersalt : an intemational study of electrolyte and blood pressure-results for 24 hour urinary sodium and potassium excretion-. Br Med J 297 : 319, 1988
 
P.23 掲載の参考文献
1) Goodman&Gilman's The Pharmacological Basis of Therapeutics, 9th Ed, ed by Hardman J G et al, McGraw-Hill, New York, 1996
 
2) 猿田亨男, 日和田邦男, 荻原俊男 (編) : Ca拮抗薬のすべて, 先端医学社, 東京, 1995
 
3) 奥西秀樹, 宮崎瑞夫 : ACE阻害薬の分類とその薬理作用-組織ACE阻害の重要性-. 治療学 30 : 863-869, 1996
Medical*Online
4) 特集「至適降圧値と至適降圧薬選択」血圧 5 : 1021-1075, 1998
 
5) 1999 WHO/ISH Guidlines for the management of hypertension. J Hypertension 17 : 151-183, 1999
 
6) STOP-Hypertension-2 study group. Lancet 354 : 1751-1756, 1999
 
P.29 掲載の参考文献
1) Levy D et al : Prognostic Implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 322 : 1561-1566, 1990
PubMed
2) May GS et al : Areview of long-term beta-blocker trials in survivors of myocardial infarction. Circulation 67 (suppl 1) : 1-46-1-49, 1983
 
3) Pfeffer MA et al : Effect of captopril on mortality and mobidity in patients with left ventricular dysfunction after myocardial infarction-results of the survival and ventricular enlargement trial-. N Engl J Med 327 : 669, 1992
 
4) Pitt B et al. : Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 349 : 747, 1997
PubMed
5) Brenner BM et al : Dietary protein intake and the progressive nature of kidney disease-the role of hemodinamically mediated glomenllar injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation and intrinsic renal disease-. N Engl J Med 307 : 652, 1982
 
6) UK Prospective diabetes Study Group : Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes-UKPDS 39-. BMJ 317 : 713, 1998
Medical*Online
7) Christlieb AR : Treatment selection considerations for hypertensive diadetic patient. Arch Intern Med 150 : 1167, 1990
 
8) Pollare T et a1 : A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321 : 868, 1989
 
9) Castelli WP et al : A population at riskprevalence of high cholesterol levels in hypertensive patients in the Framingham study-. Am J Med 80 (Suppl 2A) : 23-32, 1986
 
P.36 掲載の参考文献
1) 菊池健次郎, 長谷部直幸 : カルシウム拮抗薬をいかに用いるか-短時間作用型と長時間作用型との差異-. Medical Practice 14 : 65-70, 1997
Medical*Online
2) 長谷部直幸, 藤野貴行, 菊池健次郎 : Ca拮抗薬の治療上の注意点. 血圧 2 : 691-696, 1995
Medical*Online
3) Psaty BM, Heckbert SR, Koepsell TD et al : The risk of myocardial infarction associated with antihypertensive drugs therapies. JAMA 274 : 620-625, 1995
PubMed
4) Furberg CD, Psaty BM, Meyer JV : Nifedipine-dose-related increase in mortality in patients with coronary heart disease-. Circulation 92 : 1326-1331, 1995
PubMed
5) Kaplan NM : The calcium channel blocker controversy. Hypertens Res 19 : 57-64, 1996
 
6) Gong L, Zhang W, Zhu Y et al : Shanghai trial of nifedipine in the elderly (STONE). JHypertens 14 : 1237-1245, 1996
 
7) Staessen JA, Fagard R, Thijs Let al for the systolic hypertension in Europe (Syst-Eur) trial Investigators : Randomized double-blind comparison of placebo and activer treatment for older patients with isolated systolic hypertension. Lancet 350 : 757-764, 1997
 
8) Hansson L, Zanchetti A, Carrnthers SG et al for the HOT study group : Effects of intensive bloodpressure lowerling and low-dose aspirin in patients with hypertension-principal results of the hypertension optimal treatment (HOT) randomised trial-. Lancet 351 : 1755-1762, 1998
 
9) Hansson L, Lindholm LH, Ekbom T et al : Randomised trial of old and new antihypertensive drugs in elderly patients-cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study-. Lancet 354 : 1751-1756, 1999
PubMed
P.42 掲載の参考文献
1) 塩之入洋ほか : 臨床成人病 24 : 527, 1994
 
2) 日和田邦男ほか : 日老医誌 36 : 576, 1999
 
3) Reaven GM : Diabetes 37 : 1595, 1988
PubMed
4) The CONSENSUS Trial Study Group : N Engl J Med 316 : 1429, 1992
 
5) Pfeffer M A et al : N Engl J Med 327 : 669, 1992
PubMed
6) Taguma Y et al : N Engl J Med 313 : 1429, 1985
 
P.47 掲載の参考文献
1) 荒川規矩男ほか : 本態性高血圧症に対するTCV-116 (candesartan cilexetil) の臨床的有用性-マレイソ酸エナラプリルを対照薬とした二重盲検群間比較試験-. 臨床医薬 12 : 2613-2661, 1996
 
2) 吉永馨ほか : MK-954 (losartan potassium) の本態性高血圧症に対する前期第I相試験-血圧日内変動に及ぼす影響の検討-. 臨床医薬 10 (suppl 6) : 31-47, 1994
 
3) 柊山幸志郎ほか : アソジオテンシン I受容体拮抗薬TCV-116 (candesartan cilexetil) の本態性高血圧症における長期投与による有効性及び安全性の検討. 臨床医薬12 : 3329-3364, 1996
 
4) 荻原俊男ほか : 高齢高血圧症患者に対するアンジオテンシン I受容体拮抗薬TCV-116 (candesartan cilexetil) の降圧効果および安全性の検討. 臨床医薬 12 : 3211-3228, 1996
 
5) Gottlieb S S et al : Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 88 [part 1] : 1602-1609, 1993
 
6) Crozier I et al : Losartan in heart failure hemodynamic effects and tolerability-losartan hemodynamic study group-. Circulation 91 : 691-697, 1995
 
7) Pitt B et al : Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 349 : 747-752, 1996
 
8) Hamroff G, et al : Addition of Angiotensin I Receptor biockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 99 : 990-992, 1999
 
9) The RESOLVD pilot study investigators : Comparison of candesartan, enalapril, and their combination in congestive heart failure -randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study- : Circulation 100 : 1056-1064, 1999
PubMed
P.54 掲載の参考文献
1) Guidelines Subcommittee : 1999 World Health Organization-Intemational Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17 : 151-183, 1999
 
2) Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthers G, Floras JS, Haynes RB, Honos G, Leeman FHH, Leiter LA, Logan AG, Myers MG, Spence D, Zamke KB, for the Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension : 1999 Canadian recommendations for the Management of Hypertension. Can Med Assoc J 161 (12 suppl) : S1-S17, 1999
 
3) Ramsey LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, Poulter NR, Russell G for the British Society of Hypertension : Guidelines, for management of hypertension-report of the third working party of the British Society of Hypertension-. J Hum Hypertens 13 : 569-592, 1999
 
4) The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, The National High Blood Pressure Education Program Coordinating Committee : The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157 : 2413-2446, 1997
 
5) Jonas M, Reicher-Reiss H, Boyko V, Shotan A, Mandelzweig L, Goldbourt U, Behar S, for the Bezafibrate Infarction Prevention (BIP) Study Group : Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Med 77 : 1273-1277, 1996
 
6) Grimm RH Jr, Grandis GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM, Yunis C, Svendsen K, Liebson PR, Elmer PJ, Stamler J, for the TOMHS Research Group : Long-term effects on sexual function of five antilypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study. Hypertension 29 : 8-14, 1997
 
P.60 掲載の参考文献
1) Saito F, Kimura G : Antihypertensive mechanism of diuretics based on pressure-natriuresis relationship. Hypertension 27 : 914-918, 1996
PubMed
2) Uzu T, Kimura G : Diuretics shift circadian rhythm of blood pressure from non-dipper to dipper in essential hypertension. Circulation 100 : 1635-1638, 1999
 
3) Kimura G, Brenner BM : The renal basis for salt sensitivity in hypertension. Hypertension -Pathophysiology, Diagnosis and Management-, 2nd Ed, ed by Laragh JH and Brenner BM, Raven Press, New York, p 1569-1588, 1995
 
4) 木村玄次郎 : 腎性機序に基づいた高血圧の新しい分類. 日腎誌 36 : 1075-1081, 1994
 
5) Kimura G et al : High sodium sensitivity and glomenllar hypertension/hyperfiltration in primary aldosteronism. J Hypertens 14 : 1463-1468, 1996
PubMed
6) Kimura G : Editorial Review ; Sodium sensitivity of blood pressure-A new prognostic factor in hypertension-. Nephron 83 : 97-105, 1999
 
7) 木村玄次郎, 池田正男 : 病態生理に基づいた降圧剤の選択-とくに血管障害を合併する場合-. 臨床と研究 62 : 117-125, 1985
 
8) Kimura G et al : Hypotensive mechanisms of antihypertensives based on the water tank model. Am J Hypertens 2 : 532-536, 1989
PubMed
9) 木村玄次郎 : 腎と高血圧-病態生理からのアプローチ-, 東京医学社, 東京, 1998
 
10) Uzu T, et al : Sodium restriction shifts circadian rhythm of blood pressure from nondiper to dipper in essential hypertension. Circulation 96 : 1859-1862, 1997
PubMed
11) Morimoto A et al : Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 350 : 1734-1737, 1997
PubMed
P.64 掲載の参考文献
1) 藤井潤, 芦田映直 : 降圧剤の選び方と使い方, 第2版, 60-64頁, 南江堂, 東京, 1996
 
2) 藤井潤, 関顕 : 長期降圧剤療法の維持. 日本医事新報 3059 : 3-7, 1982
 
3) Eisen SA, Miller DK, Woodward RS et al : The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 150 : 1881-1884, 1990
PubMed
4) The sixth report of the Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure Arch Intern Med 157 : 2413-2445, 1997
PubMed
5) Rudd P : Clinicians and patients with hypertension-Unsettled issues about compliance-. Am Heart J 130 : 572-579, 1995
PubMed
6) Croog S, Levine S, Testa MA et al : The effects of antihypertensive therapy on the quality of life. N Engl J Med 314 : 1657-1664, 1986
 
7) Beto JA, Bansal VK : Quality of life in treatment of hypertension-a metaanalysis of clinical trials-. Am J Hypertens 5 : 125-133, 1992
PubMed
8) Hjemdahl P, Wiklund IK : Qualty of life on antihypertensive drug therapy--scientific end-point or marketing exercise? -. J Hypertens 10 : 1437-1446, 1992
PubMed
9) Boissel J-P, Collet J-P, Lion L et al : A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients-field trial in general practice-. J Hypertens 13 : 1059-1067, 1995
 
10) 吉田馨 : 高齢者高血圧患者のQOL-患者・医療関係-. Therapeutlc Res 14 : 3327-3331, 1993
 
P.69 掲載の参考文献
1) The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157 : 2413-46, 1997
PubMed
2) Guidelines subcommittee. 1999 World Health Organization-Intemational Society of Hypertension guidelines for the management of hypertension. J Hypertens 17 : 151-183, 1999
 
3) 後藤淳郎 : 高血圧診療の問題点. 日本医事新報 3940 : 26-32, 1999
Medical*Online
P.73 掲載の参考文献
1) 島田潔, 桑島巌, 豊島孝道ほか : 高齢者高血圧症における降圧薬の使用状況と合併症の検討-老人専門病院における調査-. Geriatric Medicine 36 : 1531-1536, 1996
 
2) Kuwajima I, Suzuki Y, Shimosawa T et al : Dimminished noctumal decline in blood pressure in elderly hypertensive patients with left ventricular hypertrophy. Am Heart J 123 : 1307-1311m 1992
 
3) Shimada K, Kawamoto A, Matsubayashi K et al : Diumal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens 10 (8) : 875-878, 1992
 
4) SHEP : Implications of the systolic hypertension in the elderly program. Hypertension 21 : 335-343, 1993
 
5) Staessen JA, Fagard R et al : Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350 : 757-763, 1997
PubMed
6) Liu L, Wang G, Gong L et al : Comparison of active treatment and placebo in older chinese patients with isolated systolic hypertension. J Hypertens 12 (1) : 1823-1830, 1998
 
7) NICS-EH study group : Randomized double-blind comparison of a calcium antagonist and a diuretics in elderly hypertensives. Hypertension 34 : 1129-1133, 1999
 
8) Pitt B, Arbor A : Angiotensin II receptor blocker vs ACE in hibitor in severe heart failure (ELITE II). 第72回AHAmeeting, 1999
 
P.77 掲載の参考文献
1) Cunningham F G, Lindheimer M D : Hypertension in pregnancy. N Engl J Med 326 : 927-932, 1992
PubMed
2) Bellomo G, Narducci P, Rondoni F et al : Prognostic value of 24-hour blood pressure in pregnancy. JAMA 282 : 1447-1452, 1999
PubMed
3) Sibai B M : Treatment of hypertension in pregnant women. N Engl J Med 335 : 257-265, 1996
PubMed
4) Barron W M, Murphy M B, Lindheimer M D : Management of hypertension during pregnancy. Hypertension-Pathophysiology, Diagnosis, and Management-, ed by Laragh J H and Brenner B M, Raven Press, New York, p 1809-1827, 1990
 
5) Redman CWG : Hypertension in pregnancy. Textbook of Hypertension, ed by Swales J D S, Blackwell Scientific Publications, London, p 767-784, 1994
 
6) Imperiale T F, Petrulis A S : A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease. JAMA 266 : 261-265, 1991
 
7) Collaborative Low-dose Aspirin Study in Pregnancy : CLASP-a randomised trial of low-dose aspirin for the prevention and treatment of preeclampsia among 9364 pregnant women-. Lancet 343 : 619-629, 1994
PubMed
8) Belizan J M, Villar J, Gonzalez L et al : Calcium supplementation to prevent hypertensive disorders of pregnancy. N Engl J Med 325 : 1399-1405, 1991
PubMed
9) Levine RJ, Hauth JC, Curet LB et al : Trial of calcium to prevent preeclampsia. N Engl J Ned 337 : 69-76, 1997
 
P.81 掲載の参考文献
1) 内山聖 : 疫学と高血圧の判定基準. 小児科臨床 52 (増刊号) : 1254-1258, 1999
 
2) 内山聖 : 小児高血圧の診断と治療. 循環器科 46 (Suppl. 1) : 574-580, 1999
 
3) 内山聖 : 小児高血圧とACE阻害薬. ACE阻害薬のすべて 改訂第3版, 日和田邦男ほか編, 先端医学社, 東京, 160-164頁, 1999
 
4) 内山聖 : 小児高血圧とCa拮抗薬. Ca拮抗薬のすべて 改訂版, 猿田享男ほか編, 先端医学社, 東京, 200-204頁, 1999
 
P.86 掲載の参考文献
1) Treatment of hypertension-drug therapy-. Clinical Hypertension, 6th Ed, ed by Kaplan NM, Williams&Wilkins, Baltimore, p 191-280, 1994
 
2) Drug therapy. Hypertension-pathophysiology, diagnosis, and management-, 2nd Ed, ed by Laragh JH, Brenner BM, Raven Press, New York, p 2741-3045, 1995
 
3) The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC W). Arch Intern Med 157 : 2413-2446, 1997
 
4) 高血圧診療のてびき : 厚生省・日本医師会編, 日本医事新報社, 東京, 1990
 
5) Kaplan NM : The calcium channel blocker controversy. Hypertens Res 19 : 57-64, 1996
 
6) Pahor M, Guralnik JM, Salive ME et al : Do calcium channel blockers increase the risk of cancer? Am J Hypertens 9 : 695-699, 1996
PubMed
7) Pahor M, Guralnik JM, Furberg CD et al : Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 347 : 1061-1065, 1996
PubMed
P.90 掲載の参考文献
1) The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure : The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 153 : 154-185, 1993
PubMed
2) 瀧下修一 : 高血圧治療-併用療法のポイント-. Mebio 13 (4) : 83-88, 1996
 
3) 瀧下修一 : 薬物相互作用と降圧薬療法. 最新医学 51 : 721-731, 1996
Medical*Online
4) 大橋京一 : 降圧薬と他薬との干渉. 高血圧をめぐる話題, 猿田享男編, 興和株式会社, 東京, 192-195頁, 1994
 
5) 厚生省長寿科学総合研究「老年者高血圧の長期予後に関する研究」班 : 老年者の高血圧治療ガイドライン-1999年改訂版- 日老医誌 36 : 576-603, 1999
 
P.95 掲載の参考文献
1) National High Blood Pressure Education Program : National high blood pressure education program working group on hypertension and chronic renal failure. Arch Intern Med 151 : 1280-1287, 1991
 
2) Peterson JC, Adler S, Burkart JM et al : Blood pressure control, proteinuria, and the progression of renal disease-the modification of diet in renal disease study-. Ann Intern Med 123 : 754-762, 1995
PubMed
3) 阿部圭志 : II. 慢性腎疾患の内科的治療分科会報告. A) 高血圧のコントロールと降圧剤の選択. 厚生省進行性腎障害調査研究班 (班長黒川清) 平成5年度研究業績集, 39-50頁, 1994
 
4) 阿部圭志 : III. 慢性腎疾患の内科的治療分科会報告. A) 降圧療法の基準 : 血圧値と降圧剤. 厚生省進行性腎障害調査研究班 (班長黒川清) 平成7年度研究業績集, 25-32頁, 1996
 
5) Maki DD, Ma JZ, Loui TA et al : Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 155 : 1073-1080, 1995
 
6) Anderson S, Diamond JR, Karnovsky MJ et al : Mechanisms underlying transition from acute glomerular injury to glomerulosclerosis in a rat model of nephrotic syndrome. J Clin Invest 82 : 1757-1768, 1988
 
7) Yoshida Y, Kawamura T, Ikoma M et al : Effects of antihypertensive drugs on glomerular morphology. Kidney Int 36 : 626-635, 1989
PubMed
8) Ito S, Abe K : Influence of anti-hypertensive drugs on glomemlar hemodynamics. Jpn J Nephrol 38 : 115-118, 1996
 
9) Gansevoort RT, de Zeeuw D, de Jong PE : Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 45 (3) : 861-867, 1994
PubMed
10) Russo D, Pisani A, De Nicola L et al : Additive antiproteinuric effect of converting enzyme inhibitor (CEI) and losartan (LOS) in normotensive patients with IgA nephropathy (IgAN). JAm Soc Nephrol 9 :97A, 1998 (abstract)
 
P.99 掲載の参考文献
1) Psaty BM, Smith NL, Siscovick DS et al : Health outcomes associated with antihypertensive therapies used as first-line agents-a systematic review and meta-analysis-. JAMA 277 : 739-745, 1997
PubMed
2) 長尾哲彦, 藤島正敏 : 高血圧の臨床 1996, 脳血管障害. 最新医学 4 (臨時増刊号) : 161-170, 1996
 
3) Voke Z, Bots ML, Hofman A et al : J-shaped relation between blood pressure and stroke in treated hypertension. Hypertension 34 : 1181-1185, 1999
 
4) Dirgnal U, Pulsinelli W : Autoregulation of cerebral blood flow in experimental focal brain ischemia. J Cereb Blood Flow Metab 10 : 327-336, 1990
 
5) Kazumata K, Tanaka K, Ishikawa T et al : Dissociation of vasoreactivity to acetazolamide and hypercapnia-comparative study in patients with chronic occlusive major cerebral artery disease-. Stroke 27 : 2052-2058, 1996
 
P.103 掲載の参考文献
1) Devereux RB et al : J Am Coll Cardiol 4 : 1222, 1984
PubMed
2) Cruickshank JM et al : Lancet 8533 : 581, 1987
PubMed
P.107 掲載の参考文献
1) Kannel WB, Zhang T, Garrison RJ : Is obesityrelated hypertension less of a cardiovascular risk? -The Framingham Study-. Am J Cardiol 120 : 1195-1201, 1990
 
2) Reaven JM : Role of insulin resistance in human disease. Diabetes 37 : 1595-1607, 1988
 
P.111 掲載の参考文献
1) Itoh K, Yoshida S, and Fukuda M : The ACE inhibitor alacepril suppresses atherogenesis independent of senlm lipids in cholesterol-red rabbits. Jpn Circ J 58 (11) : 844-854, 1994
 
2) 原納優 : カルシウム拮抗薬のイソスリン感受性への影響. 実地診療におけるカルシウム拮抗薬の手引き, 日和田邦男ほか編集, 医薬ジャーナル社, 東京, 52頁, 1993
 
3) 重富秀一 : β遮断薬. Medicament News No. 1538, 6-8頁, 1997
 
4) Kasiske BL, Ma JZ, Kalil RSN et al : Effects of antihypertensive therapy on serum lipids. Ann Intern Med 122 (2) : 133-141, 1995
 
5) Marotta T, Ferrara LA, Di Marino L et al : Factors affecting lipoprotein lipase in hypertensive patients. Metabolism 44 (6) : 712-718, 1995
PubMed
P.112 掲載の参考文献
1) 村上英紀 : 高血圧症-A. 本態性高血圧-. 日和田邦男ほか編, 実地診療におけるカルシウム拮抗薬の手引, 医薬ジャーナル, 大阪, 62-63頁, 1993
 
2) 村上英紀, 國府達郎 : 降圧薬. 循環科学 11 : 966-970, 1991
 
P.114 掲載の参考文献
1) Ohashi K et al : Effects of diltiazem on the phamacokinetics of nifedipine. J Cardivasc Pharmacol 15 : 96-101, 1990
 

II. 糖尿病治療薬

P.119 掲載の参考文献
1) 堀田饒 : α-グルコシダーゼ阻害剤の適正使用. 薬局 47 (9) 1287-1292, 1996
Medical*Online
2) Holman RR, Cun CA, Tumer RC : A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U. K. Prospective Diabetes Study 44). Diabetes Care 22 (6) : 960-964, 1999
 
3) Shinozaki K, Suzuki M, Ikebuchi M et al : Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism 45 (6) 731-737, 1996
PubMed
4) Yamasaki Y, Kawamori R, Matsushima H et al : A symptomatic hyperglycaemia is associated with increased intimal plus medial thickness of the carotid artery. Diabetologia 38 (5) : 585-591, 1995
 
5) Tominaga M, Eguchi H, Manaka H et al : Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose-The Funagata Diabetes Study-. Diabetes Care 22 (6) 920-924, 1999
 
P.123 掲載の参考文献
1) Stumvoll M et al : Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333 : 550-554, 1995
PubMed
2) Bailey CJ : Biguanides and NIDDM. Diabetes Care 15 : 755-772, 1992
PubMed
3) DeFronzo RA et al : Efficasy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333 : 541-549, 1995
 
4) U. K. Prospective Diabetes Study Group : UKPDS 28-a randomized trial of efHcacy of early addition of metfomin in sulfonylurea-treated type 2 diabetes-. Diabetes Care 21 : 87-92, 1998
 
5) U. K. Prospective Diabetes Study Group : UKPDS 34-effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 352 : 854-865, 1998
 
P.127 掲載の参考文献
1) Noda Y, Mori A, Packer L : Gliclazide scavenges hydroxyl, superoxide and nitric oxide radicals-an ESR study-. Res Commun Mol Pathol Pharmacol 96 : 115-124, 1997
PubMed
2) O'Brien RC, Luo M : The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro. Metabolism 46 (Suppl 1) : 22-25, 1997
 
3) Muller G, Satoh Y, Geisen K : Extrapancreatic effects of sulfonylureas-a comparison between glimepiride and conventional sulfonylureas-. Diabetes Res Clin Pract 28 (Suppl) : S115-137, 1995
 
4) 久保田昌詞, 森島豊彦, 松久宗英ほか : Glimepiride (HOE490) の膵外作用-肝ブドウ糖取り込みに及ぼすGlimepiride 1週間反復経口投与の効果-. 糖尿病 38 : 447-453, 1995
 
5) 兼子俊男, 坂本信夫, 中川昌一ほか : インスリン非依存型糖尿病に対するグリメピリド (HOE490) の臨床評価-グリクラジドを対照とした二重盲検比較試験-. 臨床医薬 9 : 1145-1177, 1993
Medical*Online
6) Geisen K, Vegh A, Krause E et al : Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res 28 : 496-507, 1996
PubMed
7) 坂本信夫, 堀田饒, 豊田隆謙ほか : アンケート調査による日本人糖尿病の死因-1981-1990年の10年間, 1, 1648名での検討-. 糖尿病39 : 221-234, 1996
 
8) Engler RL, Yellon DM : Sulfonylurea KATp pblockade in type II diabetes and preconditioning in cardiovascular disease. Circulation 94 : 2297-2301, 1996
PubMed
P.132 掲載の参考文献
1) Malaisse WJ : Stimulation of insulin release by non-sulfonylurea hypoglycemic agents-the meglinitide family-. Horm Meta Res 27 : 263-266, 1995
 
2) 小坂樹徳ほか : 速効・短時間型血糖降下薬AY4166のイソスリソ非依存糖尿病における至適用量の検討. 薬理と臨床 7 : 669-697, 1997
 
3) 葛谷健ほか : イソスリソ非依存糖尿病に対する速効・短時間型血糖降下剤AY4166の長期投与時の有用性. 薬理と臨床 7 : 819-832, 1997
 
P.137 掲載の参考文献
1) Fujita T et al : Reduction of insulin resistance in obese and/or diabetic animals by 5- [4- (1-methylcyclohexylmethoxy) benzyl] -thiazolidine-2, 4-dione (ADD-38378, U-63, 287, ciglitazone), a new antidiabetic agents. Diabetes 32 : 804-810, 1983
 
2) 堀越大能, 藤原俊彦 : トログリタゾンの薬効と作用機序. 日本臨床 55 : 125-130, 1997
 
3) Shimabukuro M et al : Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 273 : 3547-3550, 1998
PubMed
4) Lehman J et al : An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptorγ (PPAR-γ). J Biol Chem 270 : 12953-12956, 1995
 
5) 兼子俊男ほか : イソスリン抵抗性改善薬AD-4833の食事療法のみのインスリン非依存性糖尿病における臨床評価-プラセポを対照とした二重盲検比較試験-. 臨床と研究 74 : 1491-1514, 1997
 
6) 兼子俊男ほか : インスリン抵抗性改善薬AD-4833のSU剤使用中のインスリン非依存性糖尿病における臨床評価-プラセボを対照とした二重盲検比較試験-. 臨床と研究 74 : 1415-1539, 1997
 
7) 兼子俊男ほか : インスリン非依存性糖尿病に対するAD-4833の長期投与時の臨床的有用性-後期第III相長期投与試験-. 臨床と研究 74 : 1557-1588, 1997
 
8) Yamasaki Y et al : Pioglitazone (AD-4833) amelioratesinsulin resistance in patients with NIDDM. Tohoku J Exp Med 183 : 173-183, 1997
PubMed
P.142 掲載の参考文献
1) Kawamori R, Bando K, Yamasaki Y et al : Fasting plus prandial insulin supPlements improve insulin secretory ability in non-insulin dependent diabetics. Diabetes Care 12 : 680-685, 1989
PubMed
2) The Diabetes Control and Complications Trial Research Group : The absence of a glycemic threshold for the development of long-term complication-the perspective of the diabetes control complications trial-. Diabetes 45 : 1289-1298, 1996
 
3) Shichiri M : Strict glycemic control and diabetic microvascular complications. Intern Med 36 : 144-147, 1997
PubMed
P.146 掲載の参考文献
1) Inzucchi SE et al : Efficacy and metabolic effects of metformin and troglitazone in type 2 diabetes mellitus. N Engl J Med 338 : 867-872, 1998
PubMed
2) Schwartz S et al : Effect of troglitazone in insulintreated patients with type 2 diabetes mellitus. N Engl J Med 338 : 861-866, 1998
PubMed
P.150 掲載の参考文献
1) Yoshino G, Hirano T, Kazumi T : Dyslipidemia in diabetes mellitus. Diabetes Res Clin Pract 33 : 1-14, 1996
PubMed
2) Austin MA, Breslow JL, Hennekens CH et al : Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 : 1917-1921, 1988
PubMed
3) Hirano T, Naito H, Kurokawa M et al : High prevalencc of small LDL particles in non-insulin dependent diabetic patients with nephropathy. Atherosclerosis 123 : 57-82, 1996
PubMed
4) Sparks JD, Sparks CE : Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes. J Biol Chem 265 : 8854-8862, 1990
PubMed
5) Suga A, Hirano T, Inoue S et al : Plasma leptin levels are associated with triglyceride secretion rates in VMH-lesioned obese rats. Am J physiol 276 : E650-E657, 1994
 
6) Lewis GF, Zinman B, Uffelman KD et al : VLDL production is decreased to a similar extent by acute portal vs. peripheral venous insulin. Am J physiol 267 : E566-E572, 1994
PubMed
7) Hoffmann J, Spengler M : Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients-the Essen-II Study-. Am J Med 103 : 483-490, 1997
PubMed
8) Kazumi T, Hirano T, Okada H et al : VLDL kinetics in wister fatty rats an animal model of NIDDM-effects of dietary fructose alone or in combination with pioglitazone-. Diabetes 45 : 806-811, 1996
PubMed
9) Hirano T, Yoshino G, Kazumi T : Troglitazone and small low-density lipoprotein in type 2 diabetes. Ann Intern Med 129 : 162-163, 1998
PubMed
10) Yoshino G, Furukawa S, Hirano T et al : The minimum dose of acarbose suppresses triglyceride concentration in remnant-like particles from fasted diabetic subjects. Horm Metab Res 28 : 329-330, 1996
PubMed
P.154 掲載の参考文献
1) Reaven GM : Role of insulin resistance in human disease. Diabetes 37 : 1595-1607, 1988
PubMed
2) DeFronzo RA, Ferrannini E : Insulin resistance-a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease-. Diabetes Care 14 : 173-194, 1991
PubMed
3) 広瀬寛, 河合俊英, 猿田享男 : 脂質毒性 (Lipotoxicity) とインスリン分泌/抵抗性-リスクファクター集積症候群も視野に入れて-. 医学のあゆみ 188 : 448-451, 1999
 
4) Lee Y, Hirose H et al : β-Cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats-impairment in adipocyte-β-cell relationships-. Proc Natl Acad Sci USA 91 : 10878-10882, 1994
 
5) Kannel WB, D'Agostino RB, Wilson PW et al : Diabetes, fibrinogen, and risk of cardiovascular disease-the Framingham experience-. Am Heart J 120 : 672-676, 1990
PubMed
6) Fujishima M, Kiyohara Y, Kato I et al : Diabetes and cardiovascular disease in a prospective population survey in Japan. Diabetes 45 (Suppl 3) : S14-S16, 1996
 
7) Sowers JR, Epstein M : Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. Hypertension 26 : 869-879, 1995
PubMed
8) Ogihara T, Rakugi H, Ikegami H et al : Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 8 : 316-320, 1995
PubMed
9) The fifth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC V). Arch Intern Med 153 : 154-183, 1993
PubMed
10) The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC VI). Arch Intern Med 157 : 2413-2446, 1997
 
11) Guidelines Subcommittee : 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 17 : 151-183, 1999
PubMed
12) Hansson L et al : Effects of intensive blood pressure lowering and acetylsalicylic acid in patients with hypertension -principal results of the Hypertension Optimal Treatment (HOT) randomised trial-. Lancet 351 : 1755-1762, 1998
PubMed
13) Hansson L et al : Effects of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertensives. Lancet 353 : 611-616, 1999
 
14) UK Prospective Diabetes Study Group : Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes-UKPDS 39-. BMJ 317 : 713-720, 1998
Medical*Online
15) UK Prospective Diabetes Study Group : Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes -UKPDS 38-. BMJ 317 : 703-713, 1998
Medical*Online
16) Estacio RO, Jeffers BW, Hiatt WR et al : The effect of nisoldipine as compared to enalapril on cardiovascular outcomes in patients with non-insulindependent diabetes and hypertension. N Engl J Med 338 : 645-652, 1998
 
17) Tatti P, Pahor M, Byington RP et al : Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21 : 597-603, 1998
PubMed
18) Furukawa T, Nukada T, Suzuki K et al : Voltage and pH dependent block of cloned N-type Ca2+ Channels by amlodipine. Br J Pharmacol 121 : 1136-1140, 1997
PubMed
P.159 掲載の参考文献
1) UK Prospective Diabetes Study Group : Lancet 352 : 837-853, 1998
 
2) Knatterud GL et al : University Group Diabetes Program : JAMA 240 : 37-42, 1978
PubMed
3) Malmberg K et al : J Am Coll Cardiol 26 : 57-65, 1995
 
4) Lehto S et al : Stroke 27 : 63-68, 1996
PubMed
5) Hankey GJ et al : Stroke 29 : 2491-2500, 1998
PubMed
6) McCall AL : Diabetes 41 : 557-570, 1992
PubMed
8) Lee JS et al : Diabetes 42 : 876-882, 1993
PubMed
7）Selby JV et al : Diabetes Care 18 : 509-516, 1995
PubMed
P.163 掲載の参考文献
1) 井藤英喜 : 老年者の糖尿病治療カイドライン作成に関する研究. 長寿科学総合研究 3 : 209-211, 1995
 
2) 小坂樹徳ほか : AY4166のインスリソ非依存糖尿病患者における臨床効果および安全性の検討. 薬理と臨床 7 (5) : 635-651, 1997
 
3) 大庭建三 : 老年糖尿病患者の経口血糖降下剤療法. 長寿科学総合研究 3 : 328-334, 1996
 
4) 河盛隆造 : 老年糖尿病患者のインスリン療法のあり方に関する研究. 長寿科学総合研究 3 : 335-337, 1996
 
P.168 掲載の参考文献
1) Owada M et al : Descriptive epidemiology of noninsulin dependent diabetes mellitus detected by urine glucose screening in school children in Japan. Acta Paediatr Jpn 32 : 716-724, 1990
PubMed
2) 大和田操ほか : 我が国における小児期発症NIDDMの実態. 小児内科 28 : 823-828, 1996
 
3) 似鳥嘉一, 大和田操 : 小児期発症インスリン非依存型糖尿病 (NIDDM) の管理方法に関する研究. 日大医学雑誌 56 : 537-545, 1997
 
4) 谷本由美ほか : 小児期発症NIDDMの薬物療法に関する研究. 日小児会誌 94 : 2640-2647, 1990
 
5) Owada M et al : Treatment of NIDDM in youth. Clin Pediatr 37 : 117-121, 1998
PubMed
6) 大和田操ほか : 小児期発症2型糖尿病に対する経口血糖降下薬の使用経験. Diabetes Frontia 11 : 59-63, 2000
 
P.172 掲載の参考文献
1) 大森安恵, 浜田悌二, 豊田長康ほか : 妊娠糖尿病の診断基準に関する提案. 糖尿病 41 (Suppl 2) : A91-A96, 1998
 
2) 小浜智子, 吉井知恵子, 小林功ほか : 妊婦における耐糖能異常のスクリーニング-GDMの早期診断と管理-. 産婦人科の世界 44 : 71-76, 1992
 
3) Simmons D, Robertson S : Influence of materal Insulin treatment on the infant of women with gestational Diabetes. Diabetic Medicine 14 : 762-765, 1997
 
4) Langer O, Rodriguez DA, Berkus MD et al : Intensified versus conventional management of gestational diabetes. Am J Obestet Gynecol 170 : 1036-1047, 1994
 
5) 小山晴美, 針谷昇, 名古靖 : 当院NICUにおける糖尿病母胎児の合併症, 第12回糖尿病と妊娠に関する研究会 (抄録集) 15頁
 
6) Major CA, Henry MJ, Veciana MD et al : The effect of carbohydorate restriction in patients with diet-controlled gestational diabetes. Obstet Gynecol 91 : 600-604, 1998
 
7) 小浜智子, 高木剛, 岡野浩哉ほか : 糖尿病と双胎. 産婦人科栄養代謝研究会誌 5 : 14-16, 1999
 
P.176 掲載の参考文献
1) Ikenoue T, Akiyoshi M, Fujitani S et al : Hypoglycemic and insulinotropic effects of a novel oral antidiabetic agent, (-) -N- (trans-4-isopropylcyclohexanecarbonyl) -D-phenylalanine (A-4166). British J Pharmacol 120 : 137-145, 1997
 
2) Hara T, Nakamura J, Koh N et al : An importance of carbohydrate ingestion for the expression of the effect of α-glucosidase inhibition. Diabetes Care 19 : 642-645, 1996.
 
3) Giugliano D, Quatraro A, Consoli G et al : Metformin for obese, insulin-treated diabetic patients-improvement in glycemic control and reduction of metabolic risk factors-. Eur J Pharmacol 44 : 107-112, 1993
 

III. 高脂血症治療薬

P.185 掲載の参考文献
1) 日本動脈硬化学会高脂血症ガイドライン検討委員会 : 高脂血症ガイドライン. 動脈硬化 25 (1・2) : 1-34, 1997, 動脈硬化 26 (1) : 1998
 
P.191 掲載の参考文献
1) 国民栄養の現状, 厚生の指標-国民衛生の動向-, 厚生統計協会, 96-99頁, 1996
 
2) 江草玄士, 山木戸道郎 : 日本における冠動脈疾患と高脂血症. TOKYO TANABE QUARTERLY 44 : 10-20, 1999
 
3) 日本動脈硬化学会高脂血症診療ガイドライン. 動脈硬化 25 : 1-34, 1997
 
4) Friedewald WJ, Levy RI, Fredrickson DS : Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18 : 499-502, 1972
 
5) 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42 : 385-404, 1999
 
6) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 269 : 3015-3023, 1993
 
7) 垂井清一郎 : 厚生省原発性高脂血症調査研究昭和61年度報告書, 17-29頁, 1987.
 
8) 茎田仁志, 日和田邦男 : 動脈硬化の疫学における中性脂肪の意義. Ther Res 9 : 552-557, 1991
 
9) 山下静也 : HDL-コレステロールの基準値設定のための根拠の考え方. The Lipid 8 : 49-55, 1997
 
10) Hirano K, Yamashita S, Nakajima N et al : Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan-marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity-. Arterioscler Thromb Vasc Biol 17 : 1053-1059, 1987
PubMed
P.195 掲載の参考文献
1) 近藤和雄, 平野玲子, 岩本珠美 : Medical Practice 14 : 627, 1997
Medical*Online
2) Mattson F H, Gnlndy S M : J Lipid Res 26 : 194, 1985
 
3) Hertog M G L et al : Lancet 342 : 1007, 1993
 
4) 河盛隆造, 久保田稔, 鎌田武信 : 総合臨牀 43 : 928, 1994
 
5) Gaziano J M et al : N Engl J Med 329 : 1829, 1993
PubMed
P.207 掲載の参考文献
1) Lipid Research Clinics Program : The lipid research clinics coronary primary prevention trial results. JAMA 251 : 351-374, 1984
 
2) The Scandinavian Simvastatin Survival Study
 
3) Sacks FM et al : The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 : 1001-1009, 1996
PubMed
4) The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group : Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 : 1349, 1998
 
5) Shepherd J et al : Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 : 1301-1307, 1995
PubMed
6) Downs JR, Clearfield M, Weis S et al : Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels : results of AFCAPS/TexCAPS-Air Force/Texas Coronary Atherosclerosis Prevention Study-. JAMA 279 : 1615-1622, 1998
PubMed
7) Pitt B et al : Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC-1). Am J Cardiol 72 : 31, 1993
PubMed
8) MAAS investigators : Effect of simvastatin on coronary atheroma ; the multicentre anti-atheroma study (MAAS). Lancet 344 : 633-638, 1994
 
9) Fuster V, Badimon L, Badimon JJ et al : The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326 : 310-318, 1992
PubMed
10) Egashira K, Hirooka Y, Kai H et al : Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89 : 2519-2524 (1994)
PubMed
11) Ericsson CG, Hamsten A, Nilsson J et al : Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347 : 849-853, 1996
PubMed
12) Rubins HB et al : Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol-. Veterans Afflairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group-. N Engl J Med 341 : 410-418, 1999
 
13) Ross R Atherosclerosis-an inflammatory disease-. N Engl J Med 340 : 115, 1999
PubMed
14) MCI-196北陸地区研究会 : 高コレステロール血症に対するMCI-196とブラバHMG-CoA還元酵素阻害薬との併用効果 (II) -冠動脈疾患を有する高コレステロール血症患者を対象とした試験-. 臨床医薬 12 : 14 : 1463-1489, 1996
 
15) MCI-196研究会 : 高コレステロール血症に対するMCI-196の臨床効果-二重盲検比較法による容量設定試験-. 臨床医薬 12 : 1263-1304, 1996
 
16) Kita T, Nagano Y, Yokode M, et al : Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 84 : 5928-5931, 1987
PubMed
17) Tardif JC et al : Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 337 : 365-372, 1997
PubMed
18) Alderman JD, Pasternak RC, Sacks FM et al : Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am J Cardiol 64 : 725-729, 1989
PubMed
19) Teramoto T, Yamada N, Shimano H et al : Dosedependent effect of niceritrol on plasma Lp (a). Scand J Clin Lab Invest 56 : 359-365, 1996
PubMed
20) Carlson LA, Hamsten A, Asplund A : Pronounced lowering of serum levels of lipoprotein Lp (a) in hyperlipidaemic subjects treated with nicotinic acid. J Int Med 226 : 271-276, 1989
 
21) Frick MH, Elo O, Haapa K et al : Helsinki Heart Study : peimary-pervention trial with gemfibrozil in middle-aged men with dyslipidemia-safety of treatment, changes in risk factors, and incidence of coronary heart disease-. N Engl J Med 317 : 1237-1245, 1987
 
22) Ericsson CG, Hamsten A et al : Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lanset 347 : 849-853, 1996
 
23) Vu. -Dac N, Chopin-Delannoy S, Gervois P et al : The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 273 : 25713-25720, 1998
PubMed
24) 秦葭哉ほか : イコサペント酸エチル (EPAE) の高脂血症に対する効果-Clinofibrateとの二重盲検比較試験による臨床的有用性の比較-. Geriat Med 30 : 819-852, 1992
 
25) Brown G, Albers JJ, Fisher LD et al : Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 : 1289-1298, 1990
PubMed
26) Blankenhorn DH, Nessim SA, Jonson RL et al : Benefical effects of combined corestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257 : 3233-3240, 1987
 
27) Vececk JL, Dittmeier G, Chiarelli T et al : Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol 76 : 182-184, 1995
 
28) 高脂血症治療薬 (フィプラート系薬剤, HMG-CoA還元酵素阻害剤) と横紋筋融解症. 医薬品副作用情報, No. 112, 1992
 
29) L Ross Pierce et al : Myopathy and rhabdomyolysis associated with lovastatin-Gemfibrozil combination therapy. JAMA 264 : 71, 1990
 
30) Ross R Atherosclerosis-an inflammatory disease-. N Engl J Med 340 : 115, 1999
PubMed
P.212 掲載の参考文献
1) 厚生省特定疾患原発性高脂血症調査研究班 : 昭和61年度研究報告書, 17頁, 1987
 
2) Benannte R, Reed D : Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? JAMA 263 : 393-396, 1990
 
3) The Scandianavian Simvastatin Survival Study Group : Randomized trial of Cholesterol lowering in 4444 patients with coronary heart disease-the Scandinavian simvastatin survival study (4S). Lancet 344 : 1383-1389, 1994
 
4) Kita T et al : Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 84 : 5928-5931, 1987
PubMed
P.216 掲載の参考文献
1) Natural history of aortic and coronary atherosclerotic lesions in youth. Findings from the PDAY Study. Pathological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb 13 : 1291, 1993
 
2) Tanaka K et al : A nation-wide study of atherosclerosis in infants, children and young adults in Japan. Atherosclerosis 72 : 143, 1988
 
3) 馬渕宏 : 家族性高コレステロール血症, 南江堂, 東京, 1991
 
4) Rose W et al : Familial hypercholesterolemia-report of coronary death at age 3 in a homozygous child and prenatal diagnosis in a heterozygous siblings-. J Pediatr 100 : 757, 1982
 
5) Research Committee on Serum Lipid Level Survey 1990 in Japan : J Atheroscler Thromb 2 : 122, 1996
PubMed
6) 日本動脈硬化学会高脂血症診療ガイドライン検討委員会 : 高脂血症診療ガイドライン. 動脈硬化 24 : 259, 1996
 
7) National Cholesterol Education Program-report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents-. Pediatrics 89 (suppl) : 525, 1992
 
8) Hoeg JM : Familial hypercholesterolemia-what the zebra can teach us about the horse-. JAMA 271 : 543, 1994
PubMed
P.221 掲載の参考文献
1) 都島基夫, Walter E, Weber E et al : 血栓と脂質に関する研究第4報-経口避妊薬が脂質代謝および血小板機能, 線溶凝固能に及ぼす作用の相関性について-. 血液と脈管 14 (3) : 296-305, 1983
 
2) Rifkind BM et al and Lipid Research Clinics Program : The Lipid Research Clinics Coronary Primary Prevention Trial results-1. reduction in incidence of coronary heart disease-. JAMA 251 : 351-364, 1984
 
3) 都島基夫, 京谷晋吾, 西大條靖子ほか : 早期末期動脈硬化の非侵襲的画像診断-動脈硬化の進展, 退縮に対する抗高脂血症薬単剤の効果に関する研究-. 脈管学 36 : 367-371, 1996
 
4) Fuster V, Badimon L, Badimon JJ et al : The pathogenesis of coronary artery disease and the acute coronary syndromes-second of two parts-. NEnglJMed 326 : 310-318, 1992
 
5) Walsh BM, Schiff I, Rosner B et al : Effects of postmenopausal estrogen replacement on the concentration and metabolism of plasma lipoproteins. N Engl J Med 325 : 1196-1204, 1991
 
P.226 掲載の参考文献
1) Blankenhorn D H, SeiZer R H, Crawford O W et al : Beneficial effects of colestipol niacin therapy on the common carotid artery. Circulation 88 : 20-28, 1993
 
2) Anderson T J, Meredith I T, Yeung A C et al : The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332 : 488-493, 1995
 
3) Jukema J W, Zwinderman A H, van Boven A J et al : Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. Arterioscler Thromb Vasc Biol 16 : 425-430, 1996
PubMed
P.230 掲載の参考文献
1) Kannel W B : Hypertension-relationship with other risk factors-. Drugs 31 (Suppl 1) : 1, 1986
 
2) 秦葭哉 : 合併症を伴う高脂血症治療の実際-高脂血症-. The Experiment and Therapy 630 : 16-19, 1993
 
3) Reaven G M : Role of insulin resistance in human disease. Diabetes 37 : 1595-1607, 1988
PubMed
4) Arakawa K, Sasaki J : Effect of cardiovascular drugs on serum lipoproteins. ed by Zusman R M, Cardioprotection by Converting Enzyme Inhibition, Excerpta Medica, p 47-50, 1988
 
5) Pool J L et al : Lovastatin and coadministered antihypertensive/cardiovascular agents. Hypertension 19 : 242-248, 1992
 
P.234 掲載の参考文献
1) Howard BV : Lipoprotein metabolism in diabetes mellitus. J Lipd Res 28 : 613-628, 1987
 
2) Kasama T, Yoshino G, Iwatani I et al : Increased cholesterol concentration in intermediate density lipoprotein fraction of normolipidemic non-insulindependent diabetics. Atherosclerosis 63 : 263-266, 1987
 
3) Erkelen DW : Diabetic dyslipidemia-plasma lipids and lipoprotein composition in diabetes mellitus-. The Diabetes Annual 7, ed by Marshall SM, Home PD, Alberti KGMM et al, Elsevier, Amsterdam, p 166-177, 1993
 
4) 日本動脈硬化学会高脂血症診療ガイドライン検討委員会 : 高脂血症診療ガイドライン. 1. 成人高脂血症の診断基準, 治療適応基準, 治療目標値. 動脈硬化 25 : 1-34, 1997
 
5) Pyorala K, Pedersen TR, Kjekshus J et al : Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease-a subgroup analysis of the Scandinavian Simvastatin Sirvival Study (4S) -. Diabetes Care 20 : 614-620, 1997
 
6) Goldberg RB, Melliers MJ, Sacks FM et al : Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels-subgroup analyses in the cholesterol and recurrtent events (CARE) tria1-. The Care Investigators. Circulation 98 : 2513-2519, 1998
 
P.239 掲載の参考文献
1) Scandinavian Simvastatin Survival Group : Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease-The Scandinavian Simvastatin Survival Study (4S) -. Lancet 345 : 1274-1275, 1994
 
2) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR and Braunwald E for THE CHOLESTEROL AND RECURRENT EVENTS TRIAL INVESTIGATORS. N Engl J Med 335 : 1001-1009, 1996
 
3) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol. Rubins HB, Robins SR, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 : 410-418 1999
 
4) 日本動脈硬化学会高脂血症診療ガイドライン検討委員会 : 高脂血症診療ガイドライン. 動脈硬化 25 : 1-34, 1997
 
5) 日本動脈硬化学会高脂血症診療ガイドライン検討委員会. ガイドラインについてのお知らせ. 動脈硬化 26 : i-iii, 1998
 
6) Consensus Panel Statement : Preventing heart attack and death in patients with coronary disease. Smith Jr SC, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM, Gould KL, Greenland P, Gmndy SM, Hill MN, Hlatky MA, Houston-Miller N, Krauss RM, LaRosa J, Ockene IS, Oparil S, Pearson TA, Rapaport E, Starke RD ; the secondary prevention panel. Circulation 92 : 2-4, 1995
 
P.242 掲載の参考文献
1) 赤沼安夫 : 新しい経口血糖降下剤CS-045のインスリン非依存性糖尿病に対する長期投与の臨床評価. 臨床医薬 9 : 127, 1993
 
2) Austin M A : Prospective study of small LDL as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 92 : 1770, 1995
PubMed
3) 村上透, 山田信博 : Syndrome X (Insulin resistance syndrome) の病態とその治療. 臨床成人病 25 : 349, 1995
 
4) Shimada M : Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Proc Natl Acad Sci USA 93 : 7242-7246, 1996
PubMed
5) 村上透, 山田信博 : 各種疾患と肥満-高脂血症-. 現代医療 29 : 123, 1997
 
6) 村上透, 山田信博 : 高脂血症におけるインスリン抵抗性の分子機構. 日本臨牀 57 : 21, 1999
 
P.254 掲載の参考文献
1) Lipid Research Clinics Program : The Lipid Research Clinics Coronary Primary Prevention Trial Results-I. reduction in incidence of coronary heart disease-. JAMA 251 : 351-364, 1981
 
2) Frick MH et al : Helsinki Heart Study : Primary prevention tirial with gemfibrozil in middle-aged men with dyslipidemia-safety of treatment, change in risk factors, and incidence of coronary heart disease-. N Engl J Med 317 : 1237-1245, 1987
PubMed
3) Shepherd J et al : Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 : 1301-1307, 1995
PubMed
4) Downs JR et al : Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels-results of AFCAPS/Tex-CAPS-. JAMA 279 : 1615-1622, 1998
 
5) Sacks FM et al : The effect of pravastation on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 : 1001-1009, 1996
 
6) The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group : Preventin of cardiovascular events and death with pravastation in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 : 1349-1357, 1998
 
7) Scandinavian Simvastatin Survival Study Group : Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease-The Scandinavian Simvastatin Survival Study (4S) -. Lancet 344 : 1383-1389, 1994
 

書評

最近チェックした商品履歴

Loading...